EXANE DERIVATIVES - ADAPTIMMUNE THERAPEUTICS PLC ownership

ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 89 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q4 2020. The put-call ratio across all filers is 0.77 and the average weighting 0.1%.

Quarter-by-quarter ownership
EXANE DERIVATIVES ownership history of ADAPTIMMUNE THERAPEUTICS PLC
ValueSharesWeighting
Q2 2022$206,000
-17.3%
1210.0%0.00%
Q1 2022$249,000
-45.2%
1210.0%0.00%
Q4 2021$454,000
-27.5%
1210.0%0.00%
Q3 2021$626,000
+33.8%
1210.0%0.00%
Q2 2021$468,000
-27.1%
1210.0%0.00%
Q1 2021$642,000
-1.5%
1210.0%0.00%
Q4 2020$652,000
-32.5%
1210.0%0.00%
Q3 2020$966,000
-20.2%
1210.0%0.00%
Q2 2020$1,211,000
+268.1%
1210.0%0.00%
Q1 2020$329,000
-38.7%
1210.0%0.00%
Q4 2019$537,000
+193.4%
1210.0%0.00%
Q3 2019$183,000
-62.3%
1210.0%0.00%
Q2 2019$486,000
-6.5%
1210.0%0.00%
Q1 2019$520,000
-25.3%
1210.0%0.00%
Q4 2018$696,000
-56.8%
1210.0%0.00%
Q3 2018$1,612,000
-99.0%
121
-99.1%
0.00%
-100.0%
Q2 2018$160,274,000
+18.8%
13,3720.0%0.03%0.0%
Q1 2018$134,863,00013,3720.03%
Other shareholders
ADAPTIMMUNE THERAPEUTICS PLC shareholders Q4 2020
NameSharesValueWeighting ↓
Syncona Portfolio Ltd 1,377,294$2,341,0003.33%
Matrix Capital Management Company, LP 38,974,185$66,256,0001.50%
NEA Management Company, LLC 17,082,612$29,040,0001.49%
Endurant Capital Management LP 1,824,065$3,101,0001.09%
Long Focus Capital Management, LLC 4,679,491$7,955,0000.83%
Key Client Fiduciary Advisors, LLC 416,166$707,0000.69%
PFM Health Sciences, LP 9,109,780$15,487,0000.59%
ACT CAPITAL MANAGEMENT, LLC 90,000$153,0000.21%
DAFNA Capital Management LLC 351,064$597,0000.16%
Rock Springs Capital Management LP 2,357,544$4,008,0000.12%
View complete list of ADAPTIMMUNE THERAPEUTICS PLC shareholders